Off-target effects of drugs on nuclear hormone receptors (NHRs) may result in adverse effects in multiple organs/ physiological processes. Reliable assessments of the NHR activities for drug candidates are therefore crucial for drug development. However, the highly permissive structures of NHRs for vastly different ligands make it challenging to predict interactions by examining the chemical structures of the ligands. Here, we report a detailed investigation on the agonistic and antagonistic activities of 615 known drugs or drug candidates against a panel of 6 NHRs: androgen, progesterone, estrogen a/b, and thyroid hormone a/b receptors. Our study revealed that 4.7 and 12.4% compounds have agonistic and antagonistic activities, respectively, against this panel of NHRs. Nonetheless, potent, unintended NHR hits are relatively rare among the known drugs, indicating that such interactions are perhaps not tolerated during drug development. However, we uncovered examples of compounds that unintentionally agonize or antagonize NHRs. In addition, a number of compounds showed multi-NHR activities, suggesting that the cross-talk between multiple NHRs co-operate to elicit in vivo effects. These data highlight the merits of counter screening drug candidate against NHRs during drug discovery/ development.
Adverse drug reactions (ADRs) remain a major concern during both drug development and postapproval timeframes. In the United States alone, approximately 2 000 000 significant ADRs are reported every year, among which 100 000 cases are fatalities (Scheiber et al., 2009) . ADRs may affect only a small subset of patients but can cause widespread limitation of the use of otherwise effective drugs, thus impacting patients who may benefit (Giacomini et al., 2007) . In addition, ADRs limit the use of otherwise effective drugs, which then negatively impacts the overall cost of drug development (Giacomini et al., 2007) . These facts call for early and accurate ADR assessments in the drug development process. Approximately 75% of ADRs stem from the pharmacological profile of candidate compound (Smith et al., 2006) , which was further subdivided into primary or secondary effects. In the case of primary effects, the compound acts on its intended target(s) and is the source of the toxicity. Secondary effects are due to off-target interactions. These unintended targets include enzymes, receptors, ion channels, and transporters. Thus, detailed counter screenings against a broad range of targets are helpful to reduce or avoid ADRs at an early stage. Here, we focus on nuclear hormone receptors (NHRs) that play significant roles in reproduction, development, and metabolism.
NHRs are a family of ligand-dependent transcription factors that regulate gene expression (Aranda and Pascual, 2001 ). The target genes of NHRs are involved in myriad physiological processes, including but not limited to, growth regulation, development, metabolism, and reproductive health (Mangelsdorf et al., 1995) . Despite their diverse functions, almost all NHRs share a common structure composed of two conserved domains, ie, a DNA-binding domain and a ligand-binding domain (LBD) linked by a hinge region (Owen and Zelent, 2000; Robinson-Rechavi et al., 2003) . The LBD, located by the C-terminus of the NHR, has been the focus of biomedical research as it is the site for both ligand interaction and coactivator recruitment (Greschik et al., 2002) . Nearly all LBDs share one similar topology, ie, a hydrophobic pocket surrounded by 12 a-helices (Huang et al., 2010; Wurtz et al., 1996) . As a result of this structural feature, NHRs generally favor lipophilic compounds (Huang et al., 2010) . However, it is challenging to reliably predict the NHR activities of compounds based on only chemical structure because LBDs allow binding of compounds with very diverse properties compared with other targets (Huang et al., 2010) , for example, enzymes. Structural studies revealed that the conformations of LBDs are fluid to accommodate ligands of vastly different chemical structures (Huang et al., 2010) . Indeed, NHRs bind to numerous endogenous and exogenous compounds, such as hormones, cholesterol metabolites, bile acids, fatty acids, vitamins, and xenobiotics (Ruegg et al., 2009) . These characteristics emphasize the importance of screening candidate compounds against NHRs in the drug discovery process.
From the 48 members of the human NHR family (Mangelsdorf et al., 1995) , we adopted a panel of 6 nuclear receptors, including androgen receptor (AR), progesterone receptor (PR), estrogen receptors a/b (ERa/ERb) and thyroid hormone receptors a/b (TRa/TRb). This panel of NHRs intends to provide a focus on those with key roles in reproduction and development in addition to key metabolic processes. Furthermore, these chosen 6 NHRs are all known therapeutic targets themselves, in the areas of cancer, osteoporosis, reproductive, and metabolic diseases (Ascenzi et al., 2006; Baxter and Webb, 2009; Beresford et al., 1997; Garay and Park, 2012; Huang et al., 2010; Spitz, 2009) . Interactions with these receptors are consequently of clinical relevance. Therefore, the unintended interactions of drug candidates with these receptors should be avoided. Our aim was to develop a screening approach to achieve this objective, which we illustrated in this manuscript. After developing and configuring the assays into high throughput formats, we conducted a study using a small molecule library composed of 615 known commercial drugs, each of which were tested against the 6 NHRs in our panel. Our data revealed not only the robustness of the assays used but also the rarity in which marketed drugs interfere with NHR activity in an unintended fashion. However, we did uncover examples of previously unrecognized offtarget agonism/antagonism of NHRs by several marketed drugs and explore the potential of these interactions to drive ADRs. 
MATERIALS AND METHODS

Materials
Functional Cell Assay
Each cell line was grown in large batches following the manufacturer's instructions and frozen into vials containing 40 million cells each. The reporter assays were carried out in the following 3 steps: cell seeding, compound treatment, and assay readout.
Cell seeding. Vials of the frozen cells were thawed in plating medium contains 98% phenol red-free DMEM, 2% charcoalstripped FBS (except for AR, for which 90% OPTI-MEM and 10% dialyzed FBS were used), 25 mM HEPES, 0.1 mM NEAA, 1% Lglutamate, 1 mM sodium pyruvate, 100 U/ml penicillin and streptomycin. The resulting mixture of cells and medium were plated onto the BioCoat plates at 40 ml each well. The seeding density for each receptor cell line is 15 000cells/well for AR, 22 000cells/well for PR, 18 000cells/well for ERa and ERb, 20 000cells/well for TRa, and 40 000cells/well for TRb. The cells were incubated at 37 C for about 24 h.
Compound treatment. All test compounds were first diluted into intermediate medium (100% Phenol red-free DMEM for all cell lines except for AR using 100% OPTI-MEM, 25 mM HEPES, and 100 U/ml penicillin and streptomycin) and then 6 ll of the diluted compounds were added into the 40 ll cells in each well to achieve the final treatment concentrations The cells were incubated with compounds at 37 C for about 16 h.
Assay readout. LiveBLAzer FRET-B/G Loading Kit with CCF4-AM reagents were dissolved and mixed according to the manufacturer's instructions. The resulting substrate solution was added to the cells at 8 ll per well. The assay plates were incubated in the dark at room temperature for 2 h before fluorescence measurement with an Envision Plate Reader (PerkinElmer) at the appropriate detection settings (excitation at approximately 400 nm, emission at both approximately 460 nm [blue] and approximately 535 nm [green] ). The raw data were normalized, and blue/green signal ratio was used in data analysis according to the manufacture's instruction. The reporter assays were first run as single point confirmation assays with all of the compounds at 0.6 and 6 mM concentration points in triplicate in both agonist and antagonist modes. A list of hit compounds was then generated by applying cutoffs of >25% activation in agonist mode and >35% inhibition in antagonist mode. The cutoffs percentages, referenced from previous similar HTS campaigns, were arbitrarily assigned, due to small sample size, and lack of normal distribution of the hits. These cutoff values were based on the positive and negative controls separating the hits from the inactive data cluster. The median and the normalized inter-quartile range were used as robust estimate of the assay's center and variability, respectively, as they are widely unaffected by the data outliners. As many hits have low activities, minimal desired response, a constant which shifts the threshold away from the distribution of inactive compounds although yielding biologically meaningful hits and manageable hit rates, was applied. The value of minimal desired response was determined empirically by analyzing resulting hit rates from previous Amgen HTS campaigns.
The 22-point concentration-response assays were subsequently carried out with the hit compounds generated from the single-point confirmation assay. The compounds were subjected to a 2-fold dilution using Bravo Automated Liquid Handling Platform (Agilent Technologies), yielding final compound treatment concentrations ranging from 0.01 nM to 20 mM.
For both single-point and dose response assays mentioned earlier, the high controls used for the agonist mode were 100 nM testosterone for AR, 2 mM progesterone for PR, 50 nM for 17-bestradiol ERa and ERb, 100 nM thyroxine (T4) for TRa, and 500 nM T4 for TRb; the center controls contained assay medium with no compounds. For the antagonist mode, the intermediate medium contained 10 nM testosterone for AR, 100 nM progesterone for PR, 1 nM for 17-b-estradiol ERa, 3 nM 17-b-estradiol for ERb, 15 nM T4 for TRa, and 100 nM T4 for TRb before adding test compounds. The low controls for antagonistic run contained only assay medium without compounds and agonist; the center controls contained only the agonists at the same concentrations as described earlier.
Coactivator Recruitment Assay
Coactivator recruitment assay, for AR and PR, was carried out as a paid service provided by Life Technology (Madison, Wisconsin). The measurements were carried out, in duplicate, at the varying concentrations of compound (ie, 5 nM to 100 mM).
Competition Binding Assay
Competition binding assay for AR and PR using radioactive ligands was carried out as a paid service provided by CEREP (Poitiers, France 
RESULTS
To assess the putative NHR off-target liabilities of candidate drugs, we used commercial cell-based reporter gene assays and acquired a library of 615 drugs or drug candidates (Supplementary Table 1 ). All NHR cell lines were first validated using various model compounds for their specificity and sensitivity. The representative results are shown in Table 1 . The functional cell assay was initiated by prescreening all 615 compounds in the double-concentration fashion at 0.6 and 6 mM. The prescreening was carried out in agonist and antagonist modes, both of which were performed in triplicate. Among the 615 drugs, 142 of them (Supplementary Table 1 ) exhibited >25% activation in agonist mode and/or >35% inhibition in antagonistic mode. These 142 compounds were further subjected to a detailed 22-point concentration analysis against the panel NHRs in both agonistic and antagonistic modes. The 22-point concentration analysis was performed using concentrations that ranged from 0.01 nM to 20 mM. The Z 0 factors were 0.77-0.91 for agonistic runs, and 0.69-0.91 for antagonistic runs. Table 1 summarizes the parameters of functional cellular assay. These assays identified 29 agonist hits, and 75 antagonist hits, yielding hit rates of 4.4 and 12.2%, respectively. The hit rates for individual targets are listed in Table 1 . The IC 50 values of these hits range from subnanomolar to micromolar. It is important to point out that the concentrations used for the assay do exceed the physiological or therapeutic range of the hormone/drug of interest. However, endocrine disrupting chemicals (EDCs) tend to accumulate in tissues due, in part, to their chemical properties (Talsness et al., 2008) . Therefore, the evaluation at relatively high concentrations may be appropriate, particularly for safety studies where margin of safety determinations are crucial to understanding risk and tissue levels where drug may be accumulating. In the presented study, we discuss all the identified hits (IC 50 10 mM) in the in vitro assays.
The results from these hits and their IC 50 values are listed in Table 2 for agonists and Table 3 for antagonists. In addition to the Z 0 values listed in Table 1 , our study demonstrated the sensitivity and specificity of functional cellular assays in three distinct ways. First, all known antagonists, agonists, and selective modulators within our dataset were successfully identified, as demonstrated by Estradiol (Fish and Dorfman, 1940) and 
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17a-Ethinyl estradiol (Djerassi, 2006) for ER; Flutamide (Irwin and Prout, 1973) and Testosterone (Deanesly and Parkes, 1936) for AR; as well as Gestodene (Spona and Huber, 1987) , Norethindrone (Tyler et al., 1961) , and Mifepristone (Schreiber et al., 1983) for PR. Second, the modes of action for the known ligands were also correctly identified. For example, Fulvestrant (Wakeling et al., 1991) and Tamoxifen (Jordan and Koerner, 1975) are known ER antagonists. Indeed, they showed activities only in antagonist mode, and appeared to be inactive in agonist runs. AR antagonists, Flutamide (Irwin and Prout, 1973) and Bicalutamide (Lunglmayr, 1989) , showed activity only in the AR antagonistic assay, whereas Testosterone (Deanesly and Parkes, 1936) was only identified in agonistic mode with IC 50 approximately 2 nM, similar to the previously reported value (Kemppainen et al., 1999) . Some hormone mimetics, eg, 17a-Ethinyl estradiol (ER) (Djerassi, 2006) , Oxymetholone (AR) (Pavlatos et al., 2001) , and Danazol (AR) (Donaldson, 1989) exhibited activities in both agonist and antagonist assays. Finally, the potencies of ligands against NHRs were also reliably quantified. In the case of estradiol, a 4-5 magnitude higher IC 50 values were seen in AR and PR in comparison to those of ERs. For testosterone, a 3 magnitude increased IC 50 was seen when changing receptor from AR to PR. These observations suggested that the cellular assay can reliably assess the off-target effects on NHRs.
In addition to the drugs with known intended NHR activities, several compounds or classes were discovered to have previously underappreciated effects against NHRs. These compounds can be categorized into 3 groups. The first group is steroids or steroid mimetic compounds, which were shown to be not specific as may be expected, demonstrated by the following observations: (1) progesterone analogs were active against AR and ERs, (2) estrogens were active against AR and PR, (3) glucocorticoids showed activities primarily against AR, eg, Harrison and Tattersfield (2003) and RxList (2015) . Value calculated from Cheng et al. (2013) and Salem and Najib (2012) . Note: Please set Css, AUC, does internal and molecular weight in roman Betamethasone showed an EC 50 value of 40 pM as an agonist against AR, and (4) corticosteroids exhibited nanomolar agonistic activities, primarily against PR. The second group comes from compounds whose targets are neurological or other receptors. These compounds exhibited unexpected activities against the NHRs in our panel. For example, Prochlorperazine (a dopamine receptor antagonist) and Nitrazepam (GABA receptor ligand) showed agonistic activities against ERa. Nebivolol, a b1 receptor blocker, was seen to act as an antagonist against AR, PR, ERa, ERb, and TRa. Third, drugs whose targets are not NHRs also showed activities against NHRs. These compounds include antiviral agent (Oseltamivir), cardiac glycoside (Digitoxin) and cancer drugs that act on kinases (eg, Staurosporine) or DNA (eg, Epirubicin), many of which are toxic to cells, at low concentrations which raises the possibility that cytotoxicity may produce false positives in the cell-based assay.
The coactivator recruitment assay using fluorescently labelled coactivator peptide was applied to further validate the interesting hits revealed by the cell assay. As the coactivator recruitment assay is cell-free, cytotoxic compounds shown to be active in cellular assay can be identified. In a study carried out with 30 noncytotoxic Amgen compounds, the IC 50 values determined are within approximately 2-fold difference between cell and coactivator recruitment assays (data now shown), demonstrating excellent correlation between the two orthogonal assay formats. Based on these observations, representative compounds were picked for coactivator recruitment assay. These compounds represented three types: expected known hits, known cytotoxicants, and unexpected hits (steroids and Oseltamivir). The results are summarized in Tables 2 and 3 . Expected hits like Megestrol and unexpected hits like PR-agonizing corticosteroid yielded comparable activities (EC 50 values within 1 magnitude) versus cell assay, validating the correlations between assays. As suspected, Digitoxin, Staurosporine, and Epirubicin showed no activities in coactivator recruitment assay, confirming that the observed activities of these compounds in cellular assay resulted from their cytotoxicity. Interestingly, AR agonizing glucocorticoids and Oseltamivir showed no activities in coactivator recruitment assay, despite the high potency identified by cell assay.
To further address compounds that showed discrepancies between cell and coactivator recruitment assay, glucocorticoids (Betamethasone, Prednisolone, Methylprednisolone) and Oseltamivir were further subjected to the competition binding assay carried out using radioactive ligand. As shown in Table 2 , all three glucocorticoids demonstrated AR binding activities by competing radioactive ligands. Based on the positive results observed in the binding and cellular assay, it is reasonable to suggest that glucocorticoids are true AR hits. Therefore, the negative results observed in coactivator recruitment assay might result from the lack of certain essential "factor(s)" presented in a cellular environment. However, as the discrepancy was only observed in glucocorticoids among other noncytotoxic compounds, this observation may imply a distinct molecular mechanism when glucocorticoids binds to AR, vide infra. For the case of Oseltamivir, no binding against AR and PR was observed up to 10 mM Oseltamivir. The result suggested that Oseltamivir is likely to be a false positive, potentially driven by cytotoxicity.
The distribution of NHR activities by identified hits is illustrated in Figure 1 . Among the 6 NHRs used in the primary cellular assay screening, the 3 most frequent targets for agonists were shown to be AR, PR, and ERa, where more than 20% of the NHR activities occurred. For antagonists, AR and PR were observed to be the most frequent targets. Interestingly, TRa accounts for approximately 17% antagonistic activities, comparable to that of ERa. The 27 agonists were observed to have agonistic effects with 1-4 NHRs. Norethindrone and Estradiol are active against 4 NHRs (AR, PR, ERa, and ERb) with significantly different IC 50 values. Estradiol showed subnanomolar activities against the ERs, and micromolar activities against AR and PR. Whereas the Norethindrone compounds are nanomolar agonists for AR and PR, and micromolar hits to ERs. These observations are consistent with the specificities of these hormones (or hormone mimetics). The 75 antagonists exhibited activities against 1-6 NHRs. There are 7 antagonists that showed activities against all 6 receptors, including Emetine, Digitoxin, Staurosporine, Doxorubicin, Teniposide, Camptothecin, and Epirubicin. They are submicromolar or micromolar antagonists, except for the AR activities from Teniposide, Camptothecin, and Epirubicin, for which IC 50 values below 100 nM were observed. However, based on the observations from the coactivator recruitment assay, these activities most likely result from the cytotoxicity of the compounds instead of their on-target NHR activities. One of the obvious questions is whether interactions with NHRs bear any relation to physicochemical properties of compounds. We intended to seek answers from compounds that have demonstrated clinical utility. These drugs are of distinctively different chemical structures, covering a wide range of physicochemical properties. Therefore, these compounds provided an unbiased opportunity to evaluate the molecular properties of NHR ligands. Figure 2 illustrates the global molecular properties of the 144 tested drugs as a function of number of NHR hits. For agonists, the most promiscuous compounds (active to 3 receptors) tend to have 4 hydrogen bond acceptors, 3 hydrogen bond donors. They also tend to have MW 300. These features render increased flexibility for a compound, which, in combination with the flexibilities of NHRs, are likely to account for their activities toward multiple NHRs.
Based on current data, we recommend caution on applying the NHR off-target assays when encountering compounds with the above properties. Intriguingly, the more promiscuous compounds have logP values ranging from 2.5 to 5.0. Whereas drugs with logP 5.0 showed no agonistic activities, indicating that the NHR activities are not solely logP driven as may be assumed. For the case of antagonists, the relationship of physicochemical properties with number of receptor hits is not clear. Nonetheless, decreasing the number of hydrogen bond donors and acceptors seemed to increase the number of NHR hits, however, high acceptor/donor number did not necessarily exempt a molecule from NHR activities. From a toxicological standpoint, the off-target effects from agonists are more physiologically concerning than antagonists. For example, activation of AR and ER are implicated in prostate and breast cancer, respectively (Shapiro et al., 2011) . Therefore, these results could provide some guideline when optimizing a drug candidate to reduce the 
FIG. 2. Relationship between physical chemistry properties of 144 drugs or drug candidates and their NHR activities, as agonists (n) and antagonists ().
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DISCUSSION
NHRs are important targets of numerous marketed drugs and also many exogenous chemicals/toxicants (Daston et al., 2003) . Agonizing or antagonizing the transcriptional activities of these molecules can have profound effects on critical physiological processes including reproduction, development, and metabolism (Mangelsdorf et al., 1995) . Agents that interdict NHR biology typically bind directly to the receptor by mimicking hormonal ligands (agonist or antagonist). However, the flexible property of NHR LBDs makes it challenging to predict the NHR activities by simply examining the chemical structures of drug candidates. To address this gap we developed a screening paradigm focused on a subset of NHRs with key roles in reproductive biology and key metabolic processes. We then explored the NHR activities within a library of 615 known drugs or drug candidates. These drugs cover a variety of therapeutic areas and a diversity of targets including DNA, enzymes, globular proteins, ion channels, and NHRs. As illustrated in the workflow in Supplementary Chart 1, the results from this report represented an important, first tier, step to advance the understanding of off-target activities on NHR.
It is worth mentioning that there have been several prior efforts toward this goal. For example, the BioPrint project was carried out to predict side effects from systematic profiling against receptors, transporters, and enzymes (Krejsa et al., 2003) . Although building the training set of approximately 2000 compounds, approximately 150 in vitro assays were utilized, among which competition binding assays for AR, ERa, and TR were included. There have also been efforts with exclusive focus on NHRs. Using in silico ligand-based approach, Mestres et al. (2006) revealed that 153 of 2944 drugs are active against a panel of 25 NHRs, the hit rate of which (5.2%) is comparable to what we obtained from in vitro assay. To address the unmet concerns of the structural flexibilities presented by NHRs, ie, NHRs possess high degree of structural flexibility to accommodate vastly diverse ligands, structure-based virtual screen against NHRs have also been conducted. In a study by Schapira et al. (2003) , virtual profiling was carried out using approximately 5000 compounds against 10 NHRs. Interestingly, potential promiscuity of the AR was uncovered over a variety of steroids, coinciding with what we captured by in vitro assays (vide infra). Although the target(s) would be correctly identified, the authors pointed out that the specific structural confirmation used can dictate the success of screening (Schapira et al., 2003) . VirtualToxLab, an in silico tool to forecast off-target activities, addressed this issue by sampling large variety of thermodynamically possible confirmations of both targets and ligands (Vedani et al., 2012) . Among the 16 off-targets contained in VirtualToxLab suite, there are 10 NHRs. Due to the multidimensional QSAR utilized, encouraging results on predicted K i values would be obtained in comparison to experimentally obtained IC 50 or K d values (Vedani et al., 2012) . VirtualToxLab was therefore demonstrated as a robust tool for a detailed and rigorous safety characterization for compound of interest, against a large array of targets. However, significant amount of CPU hours might be needed (average approximately 20-80 h per ligand against all targets, according to the User and Reference Manual) for the rigorous computation process. To suffice the need of screening large number of compound, high throughput profiling was carried out using experimental approach, ie, functional cell assay as described earlier. The two notable efforts come from the Tox21 and ToxCast programs (Huang et al., 2011; Rotroff et al., 2013; Thomas et al., 2012) , both of which focus on environmental chemicals with particular interests on EDCs. For example, the ToxCast library contains 309 compounds from pesticides and industrial chemicals (Rotroff et al., 2013) . Tox21 expanded the collection to over 10 000 environmental chemicals, and with additional gene reporter assay using full length ERa (Huang et al., 2014) . The overlapping NHRs between our study and these two programs include AR, ERa, and TR. Other NHRs included in the two programs were retinoid X receptor, glucocorticoid receptor (GR), peroxisome proliferator-activated receptors, and vitamin D receptor. In this context, our study focused on the aspects of drug discovery, and is geared toward detailed characterization for the off-targets effects against NHRs that are important on reproduction and metabolism.
Validated in vitro Assays
We utilized the functional cell assay as a primary screen, and the coactivator recruitment and competition binding assays as secondary and confirmatory tests. The cellular assay was observed to be sensitive, reliable (Z 0 0.69), and in good correlation with binding and coactivator assays, except for cytotoxic compounds. The coactivator recruitment and competition binding assays served to eliminate false positives contributed by cytotoxicity. From our studies, all known agonists and antagonists (eg, Estradiol, Flutamide, etc.) were correctly identified in cellular assay, and showed comparable potencies with previously reported values. It is worth noting that the cellular assays and coactivator assays are label-free, high throughput, and low cost compared with in vivo studies, hence may serve as a reliable tool to flag NHR activities in earlier development stages. Our study demonstrated <2.3% of the drugs examined had unintended agonistic activities and <7.9% had unintentional antagonistic activities, against the NHRs that are not their primary target. In this discussion, we focus on the compounds with unintended NHR activities. Compounds with unintended hits can be grouped into steroids and nonsteroids. The steroid category included glucocorticoids, corticosteroids, and other steroids that are supposed to be specific to certain NHRs yet showed activities against other NHR(s). The nonsteroids comprise a number of compounds that are cytotoxic, as demonstrated by the negative results observed in both coactivator assay and binding assay. The only possible exception is Oseltamivir, vide infra.
Steroid Compounds
As we observed from our profiling, many steroids are not as specific as intended. These unintended steroids are gonadal steroids, corticosteroids (or glucocorticoids). Among reproductive steroids, estradiol, a potent ER hormone, showed activities against AR and PR albeit at reduced potency. Flutamide and Bicalutamide also demonstrated anti-PR activities. It is tempting to speculate that our screening data may align with the Polypharmacology theory. Polypharmacology challenges the conventional concept of "one drug, one target." Instead it focuses on biochemical networks (Kell, 2013) , and emphasizes that compound activities against multiple targets are required for overall efficacy, and perhaps toxicity (Hopkins et al., 2006) . A well-studied case of Polypharmacology was illustrated by Vinclozolin, an AR antagonist (Molina-Molina et al., 2006) . In a detailed profiling study, Hopkins et al. revealed the unexpected ER agonistic activity of Vinclozolin as well as activities against an array of other NHRs, for example, antagonistic activity against AR (Molina-Molina et al., 2006) . The wide range of multi-NHR activities of Vinclozolin were suggested to contribute to its overall anti-AR effects in vivo, agreeing well with the feminization observed in animal models (Gimeno et al., 1996; MolinaMolina et al., 2006) . Discoveries from our study supporting Polypharmacology came from reproductive hormones (or analogs thereof) like 17a-Ethinyl estradiol and Megestrol. 17a-Ethinyl estradiol acted as potent ER agonist and also had submicromolar antagonistic activity against AR. The progesterone variant Megestrol acetate exhibited antagonisitic activity toward the AR with a submicromolar IC 50 value. From a biological standpoint, these observations make sense for the possible overall phenotypic consequences, as exemplified by the phenotypic feminization observed in animal models upon administration of Vinclozolin (Ila and Ilhan, 2012; Jamieson et al., 2009) . From a compound screening perspective, these results suggested that the screening of multiple NHRs is likely to be necessary to gain a comprehensive understanding to the overall in vivo consequences.
Corticosteroids, ie, Loteprednol Etabonate, Fluticasone propinoate, Flunisolide, and Triamcinolone, all exhibited agonistic activities against PR, as revealed by cellular assay. Two of the 4 corticosteroids were subjected to coactivator requirement assay, from which their agonistic PR activities were confirmed. Although not exactly expected, the PR activities by corticosteroids are not entirely surprising. Progesterone is the precursor for cortisol, as well as corticosterone because progesterone is upstream from deoxycorticosterone in the natural synthetic pathway (Baker et al., 2013; Hill et al., 2014) . In fact, corticosteroid therapy has been shown to decrease mortality and other undesired clinical symptoms in preterm infants (NIH, 1994) . Similar effects can also be achieved by progesterone supplementation (Norwitz and Caughey, 2011) . Our study demonstrated that corticosteroids have activities against PR can, which might be relevant for its clinical application in preterm birth. Along this line, in vitro assay against PR assay, along with AR assay, could be considered as a safety assay to replace ER assay, due to the higher hit rate (Table 1) .
Unlike the PR-acting corticosteroids, AR agonizing glucocorticoids identified by cellular assay are the only subgroup showed negative results in the coactivator recruitment assay, despite that these glucocorticoids are likely to be true AR hits. Indeed these glucocorticoids clearly showed binding to AR in competition binding assay (performed in duplicates) and significant activities in cell assay, yet fail to recruit AR coactivator peptide. These observations might imply that the involvement of some unique mechanisms when these steroids bind to AR, which may need further investigation. It is also worth mentioning that the AR activities from known GR ligands were also observed in Tox21 project (Huang et al., 2011) , however, competition binding and coactivator recruitment assays were not performed in their study.
Our suspicion of glucocorticoids being true AR hits might be linked to clinical observations from prostate cancer. As prostate tumor growth in cancer is androgen-driven, prostate cancer has been primarily treated by testosterone-lowering therapy (Scher and Sawyers, 2005) . This approach was shown to be effective, yet the success of which is short-lived, as it was noted that the efficiency of AR-directed therapy was hampered by the coadministration of glucocorticoids, and that glucocorticoids induce the growth of solid tumor (Arora et al., 2013; Isikbay et al., 2014) . Hence, the possible involvement of glucocorticoids with AR and prostate cancer sparked investigation from numerous researchers. In this regard, clinically relevant AR mutants (ie, T887A, W741C, L701H, and double mutants like L701H/T877A) identified from androgen-independent prostate cancer cell lines might underlie the apparent cross-talk between AR and GR pathways (Berrevoets et al., 1993; Otsuka et al., 2011; Zhao et al., 2000) . These mutations resulted in altered or broadened ligand specificities, causing the AR pathway to be activated by nonandrogen ligands (Berrevoets et al., 1993; Otsuka et al., 2011; Zhao et al., 2000) . A detailed study conducted by Krishnan et al. (2002) showed that the increased agonistic activities of glucocorticoids against AR mutants compared with wild type, although significant AR activities from glucocorticoids were also observed in the Tox21 project, vida supra (Huang et al., 2011) . Regardless, the "increased" affinity in the mutant forms of AR may not sufficiently explain the widely observed problem of short-lived success by antiandrogen treatments for prostate cancer patients, as the ligand specificities of the mutants varies significantly from one another, yet similar phenotypically observations were seen (Zhao et al., 2000) . Indeed, glucocorticoids like Triamicinolone did not exhibit any activities against the AR mutant ( Krishnan et al., 2002) .
Alternatively, our results suggested that the direct interaction between glucocorticoids and AR might partially contribute to the ineffectiveness of androgen-lowering treatment in prostate cancer. The underlying molecular reason of why glucocorticoids effectively target the AR is unclear. There have been findings suggesting a link between the AR and GR signaling pathways (Isikbay et al., 2014) . A detailed study conducted by Arora et al. (2013) demonstrated that AR and GR share overlapping transcriptomes and cistromes, hence GR could activate (restore) AR target genes. Indeed in cells engineered to overexpress GR, activation of transcriptional program that overlaps significantly with genes induced by AR were seen following the administration of glucocorticoids (Sahu et al., 2013) . It is worthy to note that a subset of tumor cells is prone to GR induction under AR inhibition (Arora et al., 2013) . In addition to the overlapping transcriptomes, some researchers have attributed the cross-talk between AR and GR to their structural similarity (Montgomery et al., 2014; Tenbaum and Baniahmad, 1997) . Although structural similarity could be a plausible hypothesis given the close relationship between AR and GR (Fig. 3) , it may still not sufficiently explain why glucocorticoids are such potent agonists against AR, as GR also exhibits structural resemblances to other NHRs including PR and ER (Fig. 3) . In the case of PR, only 1 of 5 glucocorticoids showed nanomolar activity, whereas with ER, no agonistic activities (EC 50 < 10 mM) were observed for any of the glucocorticoids that were tested. The AR-agonizing glucocorticoids being the only group that could not be confirmed using peptide coactivator suggested that the underlying mechanism might be more complicated than what has been discovered so far. Clearly further investigation is required to deconvolute these findings.
Nonsteroid Compounds
The nonsteroid compounds with unintended targets are revealed by our study were primarily composed of known cytotoxicants (eg, cancer drugs), with exception of Oseltamivir. Marketed under the trade name, Tamiflu, Oseltamivir is an antiviral drug used to treat influenza infection (Genentech USA, 2011) . A study carried out by Ila and Ilhan (2012) using human lymphocytes showed that Oseltamivir decreased the proliferation index and nuclear division index, indicating it had a mild FAN ET AL. | 291 cytotoxic effect. However, the cytotoxic effects were no longer observed when adding an exogenous metabolic activation system (S9 mix) into the cell culture, suggesting that this particular cytotoxicity could be mitigated by metabolism (Ila and Ilhan, 2012) . The mild cytotoxicity does not fully explain the positive agonistic results of Oseltamivir, observed in cellular assay. In addition, the potential impact of Oseltamivir on the reproductive system was also investigated (Greer et al., 2011; Jamieson et al., 2009; Saito et al., 2013) . In an investigation of the effect of Oseltamivir administration during pregnancy with 619 women in Japan, malformation rates of 2.6 and 1.3% were observed for Oseltamivir and Zanamivir, another Influenza drug targeting viral neuramidase (Saito et al., 2013) . These percentages are regarded as insignificant, which led to the researchers to conclude that Oseltamivir has no significant impacts on reproduction (Saito et al., 2013) . Based on these studies, and the results from competition binding assay, Oseltamivir can be ruled out as a false positive, the underlying reason for which is unclear. Enhanced understanding of the toxicity studies of Oseltamivir will help aid on this front.
Summary
Overall, our data indicate that among marketed drugs it is relatively rare for a non-NHR agonist/antagonist to interfere with NHR activity. One explanation for this may be that such effects are not tolerated during drug development and molecules with these liabilities are discontinued. This further emphasizes the importance of the early screening paradigm highlighted in our current work. With the long term goal of understanding the complexities of off-target activities against NHRs, the off-target screen described in the current manuscript represents a key step toward realizing this vision. Our study underscores important take home messages, including: (1) in vitro assays can reliably predict the NHR activities for compounds, (2) it is advantageous to evaluate the activity of compounds on multiple NHRs to aid in the understanding of possible in vivo consequences, and (3) both agonistic and antagonistic activities need to be studied to obtain comprehensive understanding of overall effects.
SUPPLEMENTARY DATA
Supplementary data are available online at http://toxsci.oxford journals.org/. Panels A-C were generated using Pymol (The PyMOL Molecular Graphics System, Version 1.5.0.4 Schrö dinger, LLC.). PDB codes: AR: 3L3X; ERa: 2P15; GR: 3E7C; PR: 2OVH. PR is the structure cocrystalized with corepresser instead of coactivator as the cases of AR and ERa. For panel D, the multiple sequence alignment was generated using ClustalW (McWilliam et al., 2013) . The phylogenetic illustration was generated using Dendroscope (Huson and Scornavacca, 2012). providing the drug compendium. The authors also thank Paul Acton and Janet Holiday from the Department of Comparative Biology and Safety Sciences at Amgen, for their diligent support in facilitating the competition binding assay with CEREP.
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